Jean Houssinot

Publications (2)9.38 Total impact

• Article: Prediction model of Parkinson's disease based on antiparkinsonian drug claims.

  Frédéric Moisan, Véronique Gourlet, Jean-Louis Mazurie, Jean-Luc Dupupet, Jean Houssinot, Marcel Goldberg, Ellen Imbernon, Christophe Tzourio, Alexis Elbaz
  [show abstract] [hide abstract]
  ABSTRACT: Drug claims databases are increasingly available and provide opportunities to investigate epidemiologic questions. The authors used computerized drug claims databases from a social security system in 5 French districts to predict the probability that a person had Parkinson's disease (PD) based on patterns of antiparkinsonian drug (APD) use. Clinical information for a population-based sample of persons using APDs in 2007 was collected. The authors built a prediction model using demographic variables and APDs as predictors and investigated the additional predictive benefit of including information on dose and regularity of use. Among 1,114 APD users, 320 (29%) had PD and 794 (71%) had another diagnosis as determined by study neurologists. A logistic model including information on cumulative APD dose and regularity of use showed good performance (c statistic = 0.953, sensitivity = 92.5%, specificity = 86.4%). Predicted PD prevalence (among persons aged ≥18 years) was 6.66/1,000; correcting this estimate using sensitivity/specificity led to a similar figure (6.04/1,000). These data demonstrate that drug claims databases can be used to estimate the probability that a person is being treated for PD and that information on APD dose and regularity of use improves models' performances. Similar approaches could be developed for other conditions.
  American journal of epidemiology 05/2011; 174(3):354-63. · 5.59 Impact Factor
• Article: Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France.

  Claudine Fayard, Audrey Bonaventure, Isabelle Benatru, Emmanuel Roze, Julien Dumurgier, Frédéric Moisan, Aïcha Soumaré, Jean Houssinot, Jean-Luc Dupupet, Jean-Louis Mazurie, Irina Balaboi, Jean-Luc Houeto, Elsa Krim, Danièle Ranoux, Marcel Goldberg, Ellen Imbernon, Thibault Moreau, Maurice Giroud, Christophe Tzourio, Alexis Elbaz
  [show abstract] [hide abstract]
  ABSTRACT: Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <60 years (n = 49) and levodopa in patients ≥70 years (n = 133). Agreement with the recommendations increased after 2000 (66.0%) compared to before (46.3%, p = 0.025). For patients <60 years, agreement increased (64.0% vs 20.2%, p = 0.017) while it remained stable (66.4% vs 70.6%, p = 0.73) in patients ≥70 years. The publication of recommendations has influenced initial treatment choices for PD in France.
  Parkinsonism & Related Disorders 05/2011; 17(7):543-6. · 3.80 Impact Factor